Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending

Reuters03-30
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending  

Overview

  • US biopharmaceutical firm's fiscal 2025 net loss narrowed yr/yr

  • Fiscal 2025 EPS loss narrowed compared to prior yr

  • Company completed three equity offerings in 2025 and early 2026, boosting cash position

Outlook

  • Reviva plans to initiate RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in mid-2026

  • Company expects trial-related activities for RECOVER-2 to start in Q2-2026, with U.S. enrollment in Q3-2026

  • Reviva believes current cash position will fund operations into Q1-2027

Result Drivers

  • R&D SPENDING - Lower research and development expenses contributed to a narrower net loss in 2025

  • CLINICAL PROGRESS - Company highlighted durable efficacy and safety data for brilaroxazine in schizophrenia, supporting ongoing regulatory efforts

Company press release: ID:nGNXGrsyb

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY EPS

-$5.48

FY Net Income

-$19.90 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $60.00, about 7,990.6% above its March 27 closing price of $0.74

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment